PTGS2 and myeloid sarcoma: Of note, despite increased mRNA expression of PTGS2 (COX2) in MS, we did not observe overall higher levels of COX2 immunoreactivity in our MS tissues compared to NNCs and also found COX2+ cells in our control tissues counter to a previous study [66].